Abstract
PD-032 - Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have